drugset
drugset / Trial / NCT06222671

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

NCT06222671 ↗

Phase 2 Recruiting 180 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect and safety of 608 in patients with nr-axSpA.

Timeline

Start
2024-03-22
Primary completion
2025-09-22
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 608 Unknown — Subcutaneous

Indications

spondyloarthropathy